Hello, everyone, and how are you today? A spring-like morning is unfolding here on the Pharmalot corporate campus, where sundry birds are chirping and a balmy breeze is floating by. Meanwhile, we are trying to hustle those short people off to the schoolhouse as we attempt to peruse some news. To cope, we are downing another cup of stimulation. What else? Feel free to join us, of course. And now, some tidbits. Have a great day and stay in touch...
Fake Avastin Lacked Active Ingredient (Reuters)
Endo Says Supply Disruption Of Painkiller Will Be Temporary (InPharm)
Lilly Faces Payment Delays From Spain And Italy (Dow Jones)
Vietnam Study Finds Bribes Dominate Medicine (Reuters)
EMA Tells Drugmakers To Trace Heparin To Slaughterhouses (InPharma Technologist)
Bill Would Allow Local Control Over Pseudoephedrine (The Oklahoman)
Glaxo And Angiochem Sign $300M Rare Disease Pact (Pharma Times)
AstraZeneca Implicated In Pricing Probe In India (IBN Live)
Bulgaria's Sopharma Probed Over Monopolistic Pricing (Novinite)
FDA Puts Bayer And J&J Clot Drug On Fast Track For ACS (Reuters)
Forest And Richter Schizophrenia Drug Met Trial Goals (Bloomberg News)
Bayer CEO Warns About Price Cuts And Innovation (Financial Times)
EDITOR'S NOTE: Please check this post for updates throughout the morning